nodes	percent_of_prediction	percent_of_DWPC	metapath
Pantoprazole—ABCB1—Mitomycin—urinary bladder cancer	0.085	0.136	CbGbCtD
Pantoprazole—ABCG2—Fluorouracil—urinary bladder cancer	0.058	0.0926	CbGbCtD
Pantoprazole—ABCG2—Carboplatin—urinary bladder cancer	0.0577	0.092	CbGbCtD
Pantoprazole—ABCG2—Cisplatin—urinary bladder cancer	0.0493	0.0786	CbGbCtD
Pantoprazole—ABCG2—Etoposide—urinary bladder cancer	0.0484	0.0773	CbGbCtD
Pantoprazole—SLCO1B1—Methotrexate—urinary bladder cancer	0.0403	0.0643	CbGbCtD
Pantoprazole—CYP3A4—Thiotepa—urinary bladder cancer	0.0386	0.0616	CbGbCtD
Pantoprazole—ABCG2—Doxorubicin—urinary bladder cancer	0.033	0.0527	CbGbCtD
Pantoprazole—ABCG2—Methotrexate—urinary bladder cancer	0.032	0.051	CbGbCtD
Pantoprazole—ABCB1—Gemcitabine—urinary bladder cancer	0.0245	0.039	CbGbCtD
Pantoprazole—CYP1A2—Fluorouracil—urinary bladder cancer	0.0239	0.0382	CbGbCtD
Pantoprazole—CYP2C9—Fluorouracil—urinary bladder cancer	0.0216	0.0344	CbGbCtD
Pantoprazole—CYP1A2—Etoposide—urinary bladder cancer	0.02	0.0319	CbGbCtD
Pantoprazole—CYP2C9—Cisplatin—urinary bladder cancer	0.0183	0.0292	CbGbCtD
Pantoprazole—ABCB1—Cisplatin—urinary bladder cancer	0.0178	0.0284	CbGbCtD
Pantoprazole—ABCB1—Etoposide—urinary bladder cancer	0.0175	0.0279	CbGbCtD
Pantoprazole—ABCB1—Doxorubicin—urinary bladder cancer	0.0119	0.019	CbGbCtD
Pantoprazole—ABCB1—Methotrexate—urinary bladder cancer	0.0115	0.0184	CbGbCtD
Pantoprazole—CYP3A4—Etoposide—urinary bladder cancer	0.0105	0.0167	CbGbCtD
Pantoprazole—CYP3A4—Doxorubicin—urinary bladder cancer	0.00713	0.0114	CbGbCtD
Pantoprazole—CYP2C19—urine—urinary bladder cancer	0.00407	0.118	CbGeAlD
Pantoprazole—CYP1A2—urine—urinary bladder cancer	0.00333	0.0964	CbGeAlD
Pantoprazole—CYP2C9—urine—urinary bladder cancer	0.00316	0.0915	CbGeAlD
Pantoprazole—ATP4A—epithelium—urinary bladder cancer	0.00308	0.0891	CbGeAlD
Pantoprazole—ATP4A—renal system—urinary bladder cancer	0.00285	0.0826	CbGeAlD
Pantoprazole—CYP3A4—urine—urinary bladder cancer	0.00241	0.0698	CbGeAlD
Pantoprazole—ATP4A—female reproductive system—urinary bladder cancer	0.00229	0.0662	CbGeAlD
Pantoprazole—SLCO1B1—renal system—urinary bladder cancer	0.00153	0.0443	CbGeAlD
Pantoprazole—ABCG2—prostate gland—urinary bladder cancer	0.00124	0.0359	CbGeAlD
Pantoprazole—SLCO1B1—female reproductive system—urinary bladder cancer	0.00123	0.0355	CbGeAlD
Pantoprazole—ABCG2—seminal vesicle—urinary bladder cancer	0.00105	0.0304	CbGeAlD
Pantoprazole—ABCG2—urethra—urinary bladder cancer	0.000831	0.0241	CbGeAlD
Pantoprazole—CYP1A2—renal system—urinary bladder cancer	0.000814	0.0236	CbGeAlD
Pantoprazole—CYP2C19—vagina—urinary bladder cancer	0.000722	0.0209	CbGeAlD
Pantoprazole—CYP2C9—female reproductive system—urinary bladder cancer	0.000619	0.0179	CbGeAlD
Pantoprazole—ABCG2—vagina—urinary bladder cancer	0.000613	0.0177	CbGeAlD
Pantoprazole—ABCB1—prostate gland—urinary bladder cancer	0.000612	0.0177	CbGeAlD
Pantoprazole—CYP3A4—renal system—urinary bladder cancer	0.000589	0.0171	CbGeAlD
Pantoprazole—ABCB1—seminal vesicle—urinary bladder cancer	0.000518	0.015	CbGeAlD
Pantoprazole—CYP3A4—female reproductive system—urinary bladder cancer	0.000472	0.0137	CbGeAlD
Pantoprazole—ABCB1—epithelium—urinary bladder cancer	0.00045	0.013	CbGeAlD
Pantoprazole—ABCB1—renal system—urinary bladder cancer	0.000417	0.0121	CbGeAlD
Pantoprazole—ABCB1—urethra—urinary bladder cancer	0.00041	0.0119	CbGeAlD
Pantoprazole—ABCG2—lymph node—urinary bladder cancer	0.000396	0.0115	CbGeAlD
Pantoprazole—ABCB1—female reproductive system—urinary bladder cancer	0.000334	0.00968	CbGeAlD
Pantoprazole—ABCB1—vagina—urinary bladder cancer	0.000302	0.00875	CbGeAlD
Pantoprazole—ABCB1—lymph node—urinary bladder cancer	0.000195	0.00566	CbGeAlD
Pantoprazole—Sweating—Doxorubicin—urinary bladder cancer	0.000106	0.000387	CcSEcCtD
Pantoprazole—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000106	0.000387	CcSEcCtD
Pantoprazole—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000105	0.000386	CcSEcCtD
Pantoprazole—Haematuria—Doxorubicin—urinary bladder cancer	0.000105	0.000385	CcSEcCtD
Pantoprazole—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000105	0.000385	CcSEcCtD
Pantoprazole—Urethral disorder—Epirubicin—urinary bladder cancer	0.000105	0.000384	CcSEcCtD
Pantoprazole—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000104	0.000382	CcSEcCtD
Pantoprazole—Epistaxis—Doxorubicin—urinary bladder cancer	0.000104	0.000381	CcSEcCtD
Pantoprazole—Sinusitis—Doxorubicin—urinary bladder cancer	0.000103	0.000379	CcSEcCtD
Pantoprazole—Immune system disorder—Methotrexate—urinary bladder cancer	0.000103	0.000378	CcSEcCtD
Pantoprazole—Dizziness—Fluorouracil—urinary bladder cancer	0.000103	0.000378	CcSEcCtD
Pantoprazole—Visual impairment—Epirubicin—urinary bladder cancer	0.000103	0.000378	CcSEcCtD
Pantoprazole—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000103	0.000377	CcSEcCtD
Pantoprazole—Chills—Methotrexate—urinary bladder cancer	0.000103	0.000376	CcSEcCtD
Pantoprazole—Diarrhoea—Cisplatin—urinary bladder cancer	0.000101	0.000371	CcSEcCtD
Pantoprazole—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000101	0.00037	CcSEcCtD
Pantoprazole—Alopecia—Methotrexate—urinary bladder cancer	0.000101	0.00037	CcSEcCtD
Pantoprazole—Vomiting—Gemcitabine—urinary bladder cancer	0.000101	0.00037	CcSEcCtD
Pantoprazole—Mental disorder—Methotrexate—urinary bladder cancer	0.0001	0.000367	CcSEcCtD
Pantoprazole—Rash—Gemcitabine—urinary bladder cancer	0.0001	0.000367	CcSEcCtD
Pantoprazole—Dermatitis—Gemcitabine—urinary bladder cancer	0.0001	0.000366	CcSEcCtD
Pantoprazole—Eye disorder—Epirubicin—urinary bladder cancer	0.0001	0.000366	CcSEcCtD
Pantoprazole—Hypersensitivity—Etoposide—urinary bladder cancer	9.99e-05	0.000366	CcSEcCtD
Pantoprazole—Tinnitus—Epirubicin—urinary bladder cancer	9.97e-05	0.000365	CcSEcCtD
Pantoprazole—Malnutrition—Methotrexate—urinary bladder cancer	9.95e-05	0.000364	CcSEcCtD
Pantoprazole—Haemoglobin—Doxorubicin—urinary bladder cancer	9.95e-05	0.000364	CcSEcCtD
Pantoprazole—Headache—Gemcitabine—urinary bladder cancer	9.95e-05	0.000364	CcSEcCtD
Pantoprazole—Flushing—Epirubicin—urinary bladder cancer	9.93e-05	0.000364	CcSEcCtD
Pantoprazole—Vomiting—Fluorouracil—urinary bladder cancer	9.93e-05	0.000364	CcSEcCtD
Pantoprazole—Rhinitis—Doxorubicin—urinary bladder cancer	9.92e-05	0.000363	CcSEcCtD
Pantoprazole—Hepatitis—Doxorubicin—urinary bladder cancer	9.9e-05	0.000362	CcSEcCtD
Pantoprazole—Haemorrhage—Doxorubicin—urinary bladder cancer	9.9e-05	0.000362	CcSEcCtD
Pantoprazole—Hypoaesthesia—Doxorubicin—urinary bladder cancer	9.85e-05	0.000361	CcSEcCtD
Pantoprazole—Rash—Fluorouracil—urinary bladder cancer	9.84e-05	0.00036	CcSEcCtD
Pantoprazole—Dermatitis—Fluorouracil—urinary bladder cancer	9.83e-05	0.00036	CcSEcCtD
Pantoprazole—Pharyngitis—Doxorubicin—urinary bladder cancer	9.82e-05	0.00036	CcSEcCtD
Pantoprazole—Headache—Fluorouracil—urinary bladder cancer	9.78e-05	0.000358	CcSEcCtD
Pantoprazole—Urinary tract disorder—Doxorubicin—urinary bladder cancer	9.77e-05	0.000358	CcSEcCtD
Pantoprazole—Oedema peripheral—Doxorubicin—urinary bladder cancer	9.75e-05	0.000357	CcSEcCtD
Pantoprazole—Dysgeusia—Methotrexate—urinary bladder cancer	9.74e-05	0.000357	CcSEcCtD
Pantoprazole—Asthenia—Etoposide—urinary bladder cancer	9.73e-05	0.000356	CcSEcCtD
Pantoprazole—Connective tissue disorder—Doxorubicin—urinary bladder cancer	9.73e-05	0.000356	CcSEcCtD
Pantoprazole—Urethral disorder—Doxorubicin—urinary bladder cancer	9.7e-05	0.000355	CcSEcCtD
Pantoprazole—Immune system disorder—Epirubicin—urinary bladder cancer	9.66e-05	0.000354	CcSEcCtD
Pantoprazole—Back pain—Methotrexate—urinary bladder cancer	9.62e-05	0.000352	CcSEcCtD
Pantoprazole—Chills—Epirubicin—urinary bladder cancer	9.6e-05	0.000352	CcSEcCtD
Pantoprazole—Pruritus—Etoposide—urinary bladder cancer	9.59e-05	0.000351	CcSEcCtD
Pantoprazole—Arrhythmia—Epirubicin—urinary bladder cancer	9.56e-05	0.00035	CcSEcCtD
Pantoprazole—Visual impairment—Doxorubicin—urinary bladder cancer	9.54e-05	0.000349	CcSEcCtD
Pantoprazole—Alopecia—Epirubicin—urinary bladder cancer	9.45e-05	0.000346	CcSEcCtD
Pantoprazole—Nausea—Gemcitabine—urinary bladder cancer	9.43e-05	0.000345	CcSEcCtD
Pantoprazole—Vomiting—Cisplatin—urinary bladder cancer	9.41e-05	0.000345	CcSEcCtD
Pantoprazole—Vision blurred—Methotrexate—urinary bladder cancer	9.38e-05	0.000343	CcSEcCtD
Pantoprazole—Mental disorder—Epirubicin—urinary bladder cancer	9.37e-05	0.000343	CcSEcCtD
Pantoprazole—Erythema multiforme—Doxorubicin—urinary bladder cancer	9.36e-05	0.000343	CcSEcCtD
Pantoprazole—Rash—Cisplatin—urinary bladder cancer	9.33e-05	0.000342	CcSEcCtD
Pantoprazole—Dermatitis—Cisplatin—urinary bladder cancer	9.32e-05	0.000341	CcSEcCtD
Pantoprazole—Malnutrition—Epirubicin—urinary bladder cancer	9.31e-05	0.000341	CcSEcCtD
Pantoprazole—Diarrhoea—Etoposide—urinary bladder cancer	9.28e-05	0.00034	CcSEcCtD
Pantoprazole—Nausea—Fluorouracil—urinary bladder cancer	9.27e-05	0.00034	CcSEcCtD
Pantoprazole—Eye disorder—Doxorubicin—urinary bladder cancer	9.25e-05	0.000339	CcSEcCtD
Pantoprazole—Ill-defined disorder—Methotrexate—urinary bladder cancer	9.23e-05	0.000338	CcSEcCtD
Pantoprazole—Tinnitus—Doxorubicin—urinary bladder cancer	9.23e-05	0.000338	CcSEcCtD
Pantoprazole—Anaemia—Methotrexate—urinary bladder cancer	9.2e-05	0.000337	CcSEcCtD
Pantoprazole—Flushing—Doxorubicin—urinary bladder cancer	9.19e-05	0.000336	CcSEcCtD
Pantoprazole—Flatulence—Epirubicin—urinary bladder cancer	9.18e-05	0.000336	CcSEcCtD
Pantoprazole—Tension—Epirubicin—urinary bladder cancer	9.14e-05	0.000335	CcSEcCtD
Pantoprazole—Dysgeusia—Epirubicin—urinary bladder cancer	9.12e-05	0.000334	CcSEcCtD
Pantoprazole—Nervousness—Epirubicin—urinary bladder cancer	9.04e-05	0.000331	CcSEcCtD
Pantoprazole—Back pain—Epirubicin—urinary bladder cancer	9.01e-05	0.00033	CcSEcCtD
Pantoprazole—Malaise—Methotrexate—urinary bladder cancer	8.97e-05	0.000329	CcSEcCtD
Pantoprazole—Dizziness—Etoposide—urinary bladder cancer	8.97e-05	0.000328	CcSEcCtD
Pantoprazole—Muscle spasms—Epirubicin—urinary bladder cancer	8.95e-05	0.000328	CcSEcCtD
Pantoprazole—Immune system disorder—Doxorubicin—urinary bladder cancer	8.94e-05	0.000327	CcSEcCtD
Pantoprazole—Vertigo—Methotrexate—urinary bladder cancer	8.94e-05	0.000327	CcSEcCtD
Pantoprazole—Leukopenia—Methotrexate—urinary bladder cancer	8.91e-05	0.000326	CcSEcCtD
Pantoprazole—Chills—Doxorubicin—urinary bladder cancer	8.88e-05	0.000325	CcSEcCtD
Pantoprazole—Arrhythmia—Doxorubicin—urinary bladder cancer	8.84e-05	0.000324	CcSEcCtD
Pantoprazole—Nausea—Cisplatin—urinary bladder cancer	8.79e-05	0.000322	CcSEcCtD
Pantoprazole—Vision blurred—Epirubicin—urinary bladder cancer	8.78e-05	0.000321	CcSEcCtD
Pantoprazole—Alopecia—Doxorubicin—urinary bladder cancer	8.75e-05	0.00032	CcSEcCtD
Pantoprazole—Cough—Methotrexate—urinary bladder cancer	8.68e-05	0.000318	CcSEcCtD
Pantoprazole—Mental disorder—Doxorubicin—urinary bladder cancer	8.67e-05	0.000318	CcSEcCtD
Pantoprazole—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.64e-05	0.000316	CcSEcCtD
Pantoprazole—Convulsion—Methotrexate—urinary bladder cancer	8.62e-05	0.000316	CcSEcCtD
Pantoprazole—Vomiting—Etoposide—urinary bladder cancer	8.62e-05	0.000316	CcSEcCtD
Pantoprazole—Malnutrition—Doxorubicin—urinary bladder cancer	8.62e-05	0.000316	CcSEcCtD
Pantoprazole—Anaemia—Epirubicin—urinary bladder cancer	8.61e-05	0.000315	CcSEcCtD
Pantoprazole—Agitation—Epirubicin—urinary bladder cancer	8.56e-05	0.000313	CcSEcCtD
Pantoprazole—Rash—Etoposide—urinary bladder cancer	8.55e-05	0.000313	CcSEcCtD
Pantoprazole—Dermatitis—Etoposide—urinary bladder cancer	8.54e-05	0.000313	CcSEcCtD
Pantoprazole—Headache—Etoposide—urinary bladder cancer	8.49e-05	0.000311	CcSEcCtD
Pantoprazole—Flatulence—Doxorubicin—urinary bladder cancer	8.49e-05	0.000311	CcSEcCtD
Pantoprazole—Arthralgia—Methotrexate—urinary bladder cancer	8.47e-05	0.00031	CcSEcCtD
Pantoprazole—Chest pain—Methotrexate—urinary bladder cancer	8.47e-05	0.00031	CcSEcCtD
Pantoprazole—Myalgia—Methotrexate—urinary bladder cancer	8.47e-05	0.00031	CcSEcCtD
Pantoprazole—Tension—Doxorubicin—urinary bladder cancer	8.46e-05	0.00031	CcSEcCtD
Pantoprazole—Dysgeusia—Doxorubicin—urinary bladder cancer	8.44e-05	0.000309	CcSEcCtD
Pantoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.41e-05	0.000308	CcSEcCtD
Pantoprazole—Malaise—Epirubicin—urinary bladder cancer	8.4e-05	0.000308	CcSEcCtD
Pantoprazole—Discomfort—Methotrexate—urinary bladder cancer	8.37e-05	0.000307	CcSEcCtD
Pantoprazole—Nervousness—Doxorubicin—urinary bladder cancer	8.37e-05	0.000306	CcSEcCtD
Pantoprazole—Vertigo—Epirubicin—urinary bladder cancer	8.37e-05	0.000306	CcSEcCtD
Pantoprazole—Syncope—Epirubicin—urinary bladder cancer	8.35e-05	0.000306	CcSEcCtD
Pantoprazole—Leukopenia—Epirubicin—urinary bladder cancer	8.34e-05	0.000305	CcSEcCtD
Pantoprazole—Back pain—Doxorubicin—urinary bladder cancer	8.33e-05	0.000305	CcSEcCtD
Pantoprazole—Muscle spasms—Doxorubicin—urinary bladder cancer	8.28e-05	0.000303	CcSEcCtD
Pantoprazole—Palpitations—Epirubicin—urinary bladder cancer	8.23e-05	0.000301	CcSEcCtD
Pantoprazole—Confusional state—Methotrexate—urinary bladder cancer	8.19e-05	0.0003	CcSEcCtD
Pantoprazole—Loss of consciousness—Epirubicin—urinary bladder cancer	8.18e-05	0.0003	CcSEcCtD
Pantoprazole—Cough—Epirubicin—urinary bladder cancer	8.13e-05	0.000298	CcSEcCtD
Pantoprazole—Anaphylactic shock—Methotrexate—urinary bladder cancer	8.12e-05	0.000297	CcSEcCtD
Pantoprazole—Vision blurred—Doxorubicin—urinary bladder cancer	8.12e-05	0.000297	CcSEcCtD
Pantoprazole—Convulsion—Epirubicin—urinary bladder cancer	8.07e-05	0.000295	CcSEcCtD
Pantoprazole—Infection—Methotrexate—urinary bladder cancer	8.07e-05	0.000295	CcSEcCtD
Pantoprazole—Nausea—Etoposide—urinary bladder cancer	8.05e-05	0.000295	CcSEcCtD
Pantoprazole—Hypertension—Epirubicin—urinary bladder cancer	8.04e-05	0.000294	CcSEcCtD
Pantoprazole—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.99e-05	0.000293	CcSEcCtD
Pantoprazole—Nervous system disorder—Methotrexate—urinary bladder cancer	7.96e-05	0.000292	CcSEcCtD
Pantoprazole—Anaemia—Doxorubicin—urinary bladder cancer	7.96e-05	0.000292	CcSEcCtD
Pantoprazole—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.95e-05	0.000291	CcSEcCtD
Pantoprazole—Arthralgia—Epirubicin—urinary bladder cancer	7.93e-05	0.00029	CcSEcCtD
Pantoprazole—Chest pain—Epirubicin—urinary bladder cancer	7.93e-05	0.00029	CcSEcCtD
Pantoprazole—Myalgia—Epirubicin—urinary bladder cancer	7.93e-05	0.00029	CcSEcCtD
Pantoprazole—Agitation—Doxorubicin—urinary bladder cancer	7.92e-05	0.00029	CcSEcCtD
Pantoprazole—Anxiety—Epirubicin—urinary bladder cancer	7.9e-05	0.000289	CcSEcCtD
Pantoprazole—Skin disorder—Methotrexate—urinary bladder cancer	7.89e-05	0.000289	CcSEcCtD
Pantoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.87e-05	0.000288	CcSEcCtD
Pantoprazole—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.85e-05	0.000288	CcSEcCtD
Pantoprazole—Discomfort—Epirubicin—urinary bladder cancer	7.83e-05	0.000287	CcSEcCtD
Pantoprazole—Malaise—Doxorubicin—urinary bladder cancer	7.77e-05	0.000285	CcSEcCtD
Pantoprazole—Dry mouth—Epirubicin—urinary bladder cancer	7.75e-05	0.000284	CcSEcCtD
Pantoprazole—Vertigo—Doxorubicin—urinary bladder cancer	7.74e-05	0.000284	CcSEcCtD
Pantoprazole—Anorexia—Methotrexate—urinary bladder cancer	7.74e-05	0.000283	CcSEcCtD
Pantoprazole—Syncope—Doxorubicin—urinary bladder cancer	7.73e-05	0.000283	CcSEcCtD
Pantoprazole—Leukopenia—Doxorubicin—urinary bladder cancer	7.71e-05	0.000282	CcSEcCtD
Pantoprazole—Confusional state—Epirubicin—urinary bladder cancer	7.66e-05	0.000281	CcSEcCtD
Pantoprazole—Palpitations—Doxorubicin—urinary bladder cancer	7.61e-05	0.000279	CcSEcCtD
Pantoprazole—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.6e-05	0.000278	CcSEcCtD
Pantoprazole—Oedema—Epirubicin—urinary bladder cancer	7.6e-05	0.000278	CcSEcCtD
Pantoprazole—Hypotension—Methotrexate—urinary bladder cancer	7.59e-05	0.000278	CcSEcCtD
Pantoprazole—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.57e-05	0.000277	CcSEcCtD
Pantoprazole—Infection—Epirubicin—urinary bladder cancer	7.55e-05	0.000277	CcSEcCtD
Pantoprazole—Cough—Doxorubicin—urinary bladder cancer	7.52e-05	0.000275	CcSEcCtD
Pantoprazole—Shock—Epirubicin—urinary bladder cancer	7.48e-05	0.000274	CcSEcCtD
Pantoprazole—Convulsion—Doxorubicin—urinary bladder cancer	7.47e-05	0.000273	CcSEcCtD
Pantoprazole—Nervous system disorder—Epirubicin—urinary bladder cancer	7.45e-05	0.000273	CcSEcCtD
Pantoprazole—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.44e-05	0.000273	CcSEcCtD
Pantoprazole—Hypertension—Doxorubicin—urinary bladder cancer	7.44e-05	0.000272	CcSEcCtD
Pantoprazole—Tachycardia—Epirubicin—urinary bladder cancer	7.42e-05	0.000272	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.4e-05	0.000271	CcSEcCtD
Pantoprazole—Skin disorder—Epirubicin—urinary bladder cancer	7.38e-05	0.00027	CcSEcCtD
Pantoprazole—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.35e-05	0.000269	CcSEcCtD
Pantoprazole—Insomnia—Methotrexate—urinary bladder cancer	7.35e-05	0.000269	CcSEcCtD
Pantoprazole—Myalgia—Doxorubicin—urinary bladder cancer	7.34e-05	0.000269	CcSEcCtD
Pantoprazole—Arthralgia—Doxorubicin—urinary bladder cancer	7.34e-05	0.000269	CcSEcCtD
Pantoprazole—Chest pain—Doxorubicin—urinary bladder cancer	7.34e-05	0.000269	CcSEcCtD
Pantoprazole—Anxiety—Doxorubicin—urinary bladder cancer	7.31e-05	0.000268	CcSEcCtD
Pantoprazole—Paraesthesia—Methotrexate—urinary bladder cancer	7.29e-05	0.000267	CcSEcCtD
Pantoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.28e-05	0.000267	CcSEcCtD
Pantoprazole—Discomfort—Doxorubicin—urinary bladder cancer	7.25e-05	0.000265	CcSEcCtD
Pantoprazole—Anorexia—Epirubicin—urinary bladder cancer	7.24e-05	0.000265	CcSEcCtD
Pantoprazole—Dyspnoea—Methotrexate—urinary bladder cancer	7.24e-05	0.000265	CcSEcCtD
Pantoprazole—Somnolence—Methotrexate—urinary bladder cancer	7.22e-05	0.000264	CcSEcCtD
Pantoprazole—Dry mouth—Doxorubicin—urinary bladder cancer	7.17e-05	0.000263	CcSEcCtD
Pantoprazole—Dyspepsia—Methotrexate—urinary bladder cancer	7.15e-05	0.000262	CcSEcCtD
Pantoprazole—Hypotension—Epirubicin—urinary bladder cancer	7.1e-05	0.00026	CcSEcCtD
Pantoprazole—Confusional state—Doxorubicin—urinary bladder cancer	7.09e-05	0.00026	CcSEcCtD
Pantoprazole—Decreased appetite—Methotrexate—urinary bladder cancer	7.06e-05	0.000259	CcSEcCtD
Pantoprazole—Oedema—Doxorubicin—urinary bladder cancer	7.03e-05	0.000258	CcSEcCtD
Pantoprazole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.03e-05	0.000258	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.01e-05	0.000257	CcSEcCtD
Pantoprazole—Fatigue—Methotrexate—urinary bladder cancer	7e-05	0.000256	CcSEcCtD
Pantoprazole—Infection—Doxorubicin—urinary bladder cancer	6.99e-05	0.000256	CcSEcCtD
Pantoprazole—Pain—Methotrexate—urinary bladder cancer	6.94e-05	0.000254	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.92e-05	0.000254	CcSEcCtD
Pantoprazole—Shock—Doxorubicin—urinary bladder cancer	6.92e-05	0.000253	CcSEcCtD
Pantoprazole—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.9e-05	0.000253	CcSEcCtD
Pantoprazole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.89e-05	0.000252	CcSEcCtD
Pantoprazole—Insomnia—Epirubicin—urinary bladder cancer	6.87e-05	0.000252	CcSEcCtD
Pantoprazole—Tachycardia—Doxorubicin—urinary bladder cancer	6.86e-05	0.000251	CcSEcCtD
Pantoprazole—Skin disorder—Doxorubicin—urinary bladder cancer	6.83e-05	0.00025	CcSEcCtD
Pantoprazole—Paraesthesia—Epirubicin—urinary bladder cancer	6.82e-05	0.00025	CcSEcCtD
Pantoprazole—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.8e-05	0.000249	CcSEcCtD
Pantoprazole—Dyspnoea—Epirubicin—urinary bladder cancer	6.78e-05	0.000248	CcSEcCtD
Pantoprazole—Somnolence—Epirubicin—urinary bladder cancer	6.76e-05	0.000247	CcSEcCtD
Pantoprazole—Anorexia—Doxorubicin—urinary bladder cancer	6.7e-05	0.000245	CcSEcCtD
Pantoprazole—Feeling abnormal—Methotrexate—urinary bladder cancer	6.69e-05	0.000245	CcSEcCtD
Pantoprazole—Dyspepsia—Epirubicin—urinary bladder cancer	6.69e-05	0.000245	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.64e-05	0.000243	CcSEcCtD
Pantoprazole—Decreased appetite—Epirubicin—urinary bladder cancer	6.61e-05	0.000242	CcSEcCtD
Pantoprazole—Hypotension—Doxorubicin—urinary bladder cancer	6.57e-05	0.000241	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.56e-05	0.00024	CcSEcCtD
Pantoprazole—Fatigue—Epirubicin—urinary bladder cancer	6.55e-05	0.00024	CcSEcCtD
Pantoprazole—Pain—Epirubicin—urinary bladder cancer	6.5e-05	0.000238	CcSEcCtD
Pantoprazole—Constipation—Epirubicin—urinary bladder cancer	6.5e-05	0.000238	CcSEcCtD
Pantoprazole—Urticaria—Methotrexate—urinary bladder cancer	6.45e-05	0.000236	CcSEcCtD
Pantoprazole—Abdominal pain—Methotrexate—urinary bladder cancer	6.42e-05	0.000235	CcSEcCtD
Pantoprazole—Body temperature increased—Methotrexate—urinary bladder cancer	6.42e-05	0.000235	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.41e-05	0.000235	CcSEcCtD
Pantoprazole—Insomnia—Doxorubicin—urinary bladder cancer	6.36e-05	0.000233	CcSEcCtD
Pantoprazole—Paraesthesia—Doxorubicin—urinary bladder cancer	6.31e-05	0.000231	CcSEcCtD
Pantoprazole—Dyspnoea—Doxorubicin—urinary bladder cancer	6.27e-05	0.00023	CcSEcCtD
Pantoprazole—Feeling abnormal—Epirubicin—urinary bladder cancer	6.26e-05	0.000229	CcSEcCtD
Pantoprazole—Somnolence—Doxorubicin—urinary bladder cancer	6.25e-05	0.000229	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.21e-05	0.000228	CcSEcCtD
Pantoprazole—Dyspepsia—Doxorubicin—urinary bladder cancer	6.19e-05	0.000227	CcSEcCtD
Pantoprazole—Decreased appetite—Doxorubicin—urinary bladder cancer	6.11e-05	0.000224	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.07e-05	0.000222	CcSEcCtD
Pantoprazole—Fatigue—Doxorubicin—urinary bladder cancer	6.06e-05	0.000222	CcSEcCtD
Pantoprazole—Urticaria—Epirubicin—urinary bladder cancer	6.04e-05	0.000221	CcSEcCtD
Pantoprazole—Constipation—Doxorubicin—urinary bladder cancer	6.01e-05	0.00022	CcSEcCtD
Pantoprazole—Pain—Doxorubicin—urinary bladder cancer	6.01e-05	0.00022	CcSEcCtD
Pantoprazole—Body temperature increased—Epirubicin—urinary bladder cancer	6.01e-05	0.00022	CcSEcCtD
Pantoprazole—Abdominal pain—Epirubicin—urinary bladder cancer	6.01e-05	0.00022	CcSEcCtD
Pantoprazole—Hypersensitivity—Methotrexate—urinary bladder cancer	5.98e-05	0.000219	CcSEcCtD
Pantoprazole—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	5.92e-05	0.000901	CbGpPWpGaD
Pantoprazole—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	5.91e-05	0.000899	CbGpPWpGaD
Pantoprazole—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.87e-05	0.000893	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	5.84e-05	0.000889	CbGpPWpGaD
Pantoprazole—Asthenia—Methotrexate—urinary bladder cancer	5.83e-05	0.000213	CcSEcCtD
Pantoprazole—SLCO1B1—Metabolism—PRSS3—urinary bladder cancer	5.81e-05	0.000884	CbGpPWpGaD
Pantoprazole—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.79e-05	0.000212	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.75e-05	0.000211	CcSEcCtD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.75e-05	0.000875	CbGpPWpGaD
Pantoprazole—Pruritus—Methotrexate—urinary bladder cancer	5.75e-05	0.00021	CcSEcCtD
Pantoprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	5.69e-05	0.000865	CbGpPWpGaD
Pantoprazole—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	5.67e-05	0.000863	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	5.66e-05	0.000862	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.65e-05	0.000859	CbGpPWpGaD
Pantoprazole—Hypersensitivity—Epirubicin—urinary bladder cancer	5.6e-05	0.000205	CcSEcCtD
Pantoprazole—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.59e-05	0.000851	CbGpPWpGaD
Pantoprazole—Urticaria—Doxorubicin—urinary bladder cancer	5.59e-05	0.000205	CcSEcCtD
Pantoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	5.56e-05	0.000846	CbGpPWpGaD
Pantoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	5.56e-05	0.000846	CbGpPWpGaD
Pantoprazole—Body temperature increased—Doxorubicin—urinary bladder cancer	5.56e-05	0.000204	CcSEcCtD
Pantoprazole—Abdominal pain—Doxorubicin—urinary bladder cancer	5.56e-05	0.000204	CcSEcCtD
Pantoprazole—Diarrhoea—Methotrexate—urinary bladder cancer	5.56e-05	0.000203	CcSEcCtD
Pantoprazole—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	5.52e-05	0.00084	CbGpPWpGaD
Pantoprazole—Asthenia—Epirubicin—urinary bladder cancer	5.45e-05	0.0002	CcSEcCtD
Pantoprazole—Pruritus—Epirubicin—urinary bladder cancer	5.38e-05	0.000197	CcSEcCtD
Pantoprazole—ABCG2—Metabolism—PRSS3—urinary bladder cancer	5.38e-05	0.000818	CbGpPWpGaD
Pantoprazole—Dizziness—Methotrexate—urinary bladder cancer	5.37e-05	0.000197	CcSEcCtD
Pantoprazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	5.3e-05	0.000806	CbGpPWpGaD
Pantoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	5.3e-05	0.000806	CbGpPWpGaD
Pantoprazole—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	5.27e-05	0.000802	CbGpPWpGaD
Pantoprazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	5.25e-05	0.0008	CbGpPWpGaD
Pantoprazole—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.2e-05	0.000791	CbGpPWpGaD
Pantoprazole—Diarrhoea—Epirubicin—urinary bladder cancer	5.2e-05	0.00019	CcSEcCtD
Pantoprazole—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.18e-05	0.00019	CcSEcCtD
Pantoprazole—Vomiting—Methotrexate—urinary bladder cancer	5.16e-05	0.000189	CcSEcCtD
Pantoprazole—Rash—Methotrexate—urinary bladder cancer	5.12e-05	0.000188	CcSEcCtD
Pantoprazole—Dermatitis—Methotrexate—urinary bladder cancer	5.12e-05	0.000187	CcSEcCtD
Pantoprazole—Headache—Methotrexate—urinary bladder cancer	5.09e-05	0.000186	CcSEcCtD
Pantoprazole—Asthenia—Doxorubicin—urinary bladder cancer	5.05e-05	0.000185	CcSEcCtD
Pantoprazole—Dizziness—Epirubicin—urinary bladder cancer	5.03e-05	0.000184	CcSEcCtD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	5e-05	0.000761	CbGpPWpGaD
Pantoprazole—Pruritus—Doxorubicin—urinary bladder cancer	4.98e-05	0.000182	CcSEcCtD
Pantoprazole—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	4.85e-05	0.000737	CbGpPWpGaD
Pantoprazole—Vomiting—Epirubicin—urinary bladder cancer	4.83e-05	0.000177	CcSEcCtD
Pantoprazole—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.83e-05	0.000735	CbGpPWpGaD
Pantoprazole—Nausea—Methotrexate—urinary bladder cancer	4.82e-05	0.000177	CcSEcCtD
Pantoprazole—Diarrhoea—Doxorubicin—urinary bladder cancer	4.81e-05	0.000176	CcSEcCtD
Pantoprazole—Rash—Epirubicin—urinary bladder cancer	4.79e-05	0.000175	CcSEcCtD
Pantoprazole—Dermatitis—Epirubicin—urinary bladder cancer	4.79e-05	0.000175	CcSEcCtD
Pantoprazole—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.78e-05	0.000727	CbGpPWpGaD
Pantoprazole—Headache—Epirubicin—urinary bladder cancer	4.76e-05	0.000174	CcSEcCtD
Pantoprazole—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.66e-05	0.000709	CbGpPWpGaD
Pantoprazole—Dizziness—Doxorubicin—urinary bladder cancer	4.65e-05	0.00017	CcSEcCtD
Pantoprazole—SLCO1B1—Metabolism—TYMP—urinary bladder cancer	4.64e-05	0.000706	CbGpPWpGaD
Pantoprazole—Nausea—Epirubicin—urinary bladder cancer	4.51e-05	0.000165	CcSEcCtD
Pantoprazole—Vomiting—Doxorubicin—urinary bladder cancer	4.47e-05	0.000164	CcSEcCtD
Pantoprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	4.47e-05	0.00068	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.46e-05	0.000678	CbGpPWpGaD
Pantoprazole—Rash—Doxorubicin—urinary bladder cancer	4.43e-05	0.000162	CcSEcCtD
Pantoprazole—Dermatitis—Doxorubicin—urinary bladder cancer	4.43e-05	0.000162	CcSEcCtD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.42e-05	0.000673	CbGpPWpGaD
Pantoprazole—Headache—Doxorubicin—urinary bladder cancer	4.41e-05	0.000161	CcSEcCtD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.4e-05	0.00067	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.38e-05	0.000667	CbGpPWpGaD
Pantoprazole—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	4.3e-05	0.000655	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—TYMP—urinary bladder cancer	4.3e-05	0.000654	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—NAT2—urinary bladder cancer	4.2e-05	0.000639	CbGpPWpGaD
Pantoprazole—Nausea—Doxorubicin—urinary bladder cancer	4.18e-05	0.000153	CcSEcCtD
Pantoprazole—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	4.15e-05	0.000631	CbGpPWpGaD
Pantoprazole—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.07e-05	0.000619	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	4.05e-05	0.000616	CbGpPWpGaD
Pantoprazole—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.01e-05	0.000611	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	3.93e-05	0.000598	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—NAT1—urinary bladder cancer	3.93e-05	0.000598	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—NAT2—urinary bladder cancer	3.89e-05	0.000592	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.87e-05	0.000588	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.84e-05	0.000585	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—GSTO2—urinary bladder cancer	3.84e-05	0.000584	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—NAT1—urinary bladder cancer	3.84e-05	0.000584	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.79e-05	0.000577	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	3.78e-05	0.000575	CbGpPWpGaD
Pantoprazole—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.74e-05	0.000569	CbGpPWpGaD
Pantoprazole—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.69e-05	0.000561	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	3.62e-05	0.000551	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	3.59e-05	0.000547	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	3.58e-05	0.000545	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—NAT1—urinary bladder cancer	3.58e-05	0.000545	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.52e-05	0.000536	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	3.51e-05	0.000534	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	3.36e-05	0.000511	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	3.36e-05	0.000511	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—RRM2—urinary bladder cancer	3.36e-05	0.000511	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.34e-05	0.000508	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	3.28e-05	0.000499	CbGpPWpGaD
Pantoprazole—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.26e-05	0.000496	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	3.26e-05	0.000495	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	3.24e-05	0.000492	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	3.23e-05	0.000492	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.22e-05	0.00049	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.21e-05	0.000488	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.16e-05	0.000481	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.15e-05	0.000479	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—HPGDS—urinary bladder cancer	3.11e-05	0.000473	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—ENO2—urinary bladder cancer	3.11e-05	0.000473	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	3.06e-05	0.000466	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—NAT1—urinary bladder cancer	3.06e-05	0.000466	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	3.06e-05	0.000465	CbGpPWpGaD
Pantoprazole—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.05e-05	0.000464	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—GSTT1—urinary bladder cancer	3.01e-05	0.000459	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.01e-05	0.000458	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.98e-05	0.000454	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	2.98e-05	0.000453	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.95e-05	0.000449	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.91e-05	0.000442	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.84e-05	0.000433	CbGpPWpGaD
Pantoprazole—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.82e-05	0.000429	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	2.8e-05	0.000426	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.79e-05	0.000424	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.75e-05	0.000419	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.74e-05	0.000418	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.72e-05	0.000413	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	2.71e-05	0.000412	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.62e-05	0.000399	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.62e-05	0.000398	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.54e-05	0.000387	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	2.52e-05	0.000384	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—NQO1—urinary bladder cancer	2.5e-05	0.000381	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.49e-05	0.000379	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.39e-05	0.000363	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.38e-05	0.000362	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—TYMP—urinary bladder cancer	2.38e-05	0.000362	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.36e-05	0.00036	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.36e-05	0.00036	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.32e-05	0.000354	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.32e-05	0.000353	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.29e-05	0.000348	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.29e-05	0.000348	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.28e-05	0.000347	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	2.26e-05	0.000343	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.23e-05	0.000339	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.18e-05	0.000332	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.18e-05	0.000331	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.17e-05	0.00033	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.16e-05	0.000329	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.15e-05	0.000328	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.12e-05	0.000323	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.11e-05	0.000321	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.1e-05	0.00032	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	2.1e-05	0.000319	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—GSTP1—urinary bladder cancer	2.09e-05	0.000318	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.09e-05	0.000317	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	2.07e-05	0.000316	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	2.07e-05	0.000316	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.99e-05	0.000302	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.96e-05	0.000299	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.95e-05	0.000297	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.95e-05	0.000296	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—TYMS—urinary bladder cancer	1.94e-05	0.000296	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—NCOR1—urinary bladder cancer	1.92e-05	0.000292	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—GSTM1—urinary bladder cancer	1.92e-05	0.000292	CbGpPWpGaD
Pantoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.87e-05	0.000285	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.86e-05	0.000283	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.86e-05	0.000283	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.86e-05	0.000282	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—GPX1—urinary bladder cancer	1.84e-05	0.00028	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.84e-05	0.00028	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.83e-05	0.000279	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.81e-05	0.000276	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—ERCC2—urinary bladder cancer	1.81e-05	0.000275	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.79e-05	0.000273	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.78e-05	0.000271	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.72e-05	0.000262	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.72e-05	0.000262	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.71e-05	0.00026	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—MTHFR—urinary bladder cancer	1.7e-05	0.000258	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.69e-05	0.000258	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.68e-05	0.000256	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.68e-05	0.000256	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.68e-05	0.000255	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.67e-05	0.000254	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.64e-05	0.00025	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.63e-05	0.000248	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.57e-05	0.000239	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.57e-05	0.000239	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.56e-05	0.000237	CbGpPWpGaD
Pantoprazole—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.53e-05	0.000232	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.52e-05	0.000232	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.5e-05	0.000228	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	1.49e-05	0.000226	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.45e-05	0.00022	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.43e-05	0.000218	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	1.43e-05	0.000217	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.39e-05	0.000211	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.38e-05	0.000209	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.35e-05	0.000206	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.35e-05	0.000205	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.34e-05	0.000204	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.34e-05	0.000204	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.33e-05	0.000203	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.32e-05	0.000201	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.3e-05	0.000198	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.29e-05	0.000197	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.28e-05	0.000195	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.27e-05	0.000193	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.23e-05	0.000187	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.17e-05	0.000179	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	1.17e-05	0.000178	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.16e-05	0.000176	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.13e-05	0.000172	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.12e-05	0.00017	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.12e-05	0.00017	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.08e-05	0.000165	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.08e-05	0.000165	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.08e-05	0.000164	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.07e-05	0.000163	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.06e-05	0.000162	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.06e-05	0.000162	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.06e-05	0.000161	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.05e-05	0.00016	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.05e-05	0.00016	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.04e-05	0.000158	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.04e-05	0.000158	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.04e-05	0.000158	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.04e-05	0.000158	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.02e-05	0.000155	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	1.02e-05	0.000155	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.02e-05	0.000155	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1e-05	0.000153	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1e-05	0.000152	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.94e-06	0.000151	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—TYMS—urinary bladder cancer	9.81e-06	0.000149	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—ERCC2—urinary bladder cancer	9.76e-06	0.000149	CbGpPWpGaD
Pantoprazole—SLCO1B1—Metabolism—EP300—urinary bladder cancer	9.72e-06	0.000148	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	9.7e-06	0.000148	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	9.7e-06	0.000148	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—PTEN—urinary bladder cancer	9.44e-06	0.000144	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	9.4e-06	0.000143	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—GPX1—urinary bladder cancer	9.29e-06	0.000141	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.17e-06	0.00014	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.15e-06	0.000139	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	9.12e-06	0.000139	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	9.02e-06	0.000137	CbGpPWpGaD
Pantoprazole—ABCG2—Metabolism—EP300—urinary bladder cancer	9e-06	0.000137	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.72e-06	0.000133	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	8.57e-06	0.00013	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—TYMS—urinary bladder cancer	8.38e-06	0.000128	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.34e-06	0.000127	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	8.29e-06	0.000126	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	8.29e-06	0.000126	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.94e-06	0.000121	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	7.79e-06	0.000119	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—PPARG—urinary bladder cancer	7.62e-06	0.000116	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.44e-06	0.000113	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	7.32e-06	0.000111	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	7.32e-06	0.000111	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.15e-06	0.000109	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.96e-06	0.000106	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.95e-06	0.000106	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	6.68e-06	0.000102	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.47e-06	9.85e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.4e-06	9.73e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.4e-06	9.73e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.12e-06	9.32e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.01e-06	9.15e-05	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	6e-06	9.12e-05	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.94e-06	9.04e-05	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.85e-06	8.91e-05	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.7e-06	8.68e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.65e-06	8.6e-05	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.47e-06	8.32e-05	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—PTEN—urinary bladder cancer	5.23e-06	7.96e-05	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.1e-06	7.77e-05	CbGpPWpGaD
Pantoprazole—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.99e-06	7.59e-05	CbGpPWpGaD
Pantoprazole—ABCB1—Metabolism—EP300—urinary bladder cancer	4.87e-06	7.41e-05	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.77e-06	7.26e-05	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.67e-06	7.11e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.58e-06	6.97e-05	CbGpPWpGaD
Pantoprazole—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.55e-06	6.92e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.4e-06	6.7e-05	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.07e-06	6.2e-05	CbGpPWpGaD
Pantoprazole—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.89e-06	5.91e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.61e-06	5.49e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.14e-06	4.78e-05	CbGpPWpGaD
Pantoprazole—CYP3A4—Metabolism—EP300—urinary bladder cancer	3e-06	4.56e-05	CbGpPWpGaD
